A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
Public ClinicalTrials.gov record NCT00436826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy With Interferon-beta (IFN-β) Treatment in Multiple Sclerosis Subjects With Active Disease
Study identification
- NCT ID
- NCT00436826
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Enrollment
- 172 participants
Conditions and interventions
Conditions
Interventions
- Cladribine Drug
- Placebo Drug
- Interferon-beta (IFN-beta) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2006
- Primary completion
- Sep 29, 2011
- Completion
- Mar 30, 2012
- Last update posted
- Oct 11, 2020
2006 – 2012
United States locations
- U.S. sites
- 21
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Cullman | Alabama | — | — |
| Research Site | Phoenix | Arizona | — | — |
| Research Site | Scottsdale | Arizona | — | — |
| Research Site | Los Angeles | California | — | — |
| Research Site | Boulder | Colorado | — | — |
| Research Site | Fort Collins | Colorado | — | — |
| Research Site | Tampa | Florida | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Peoria | Illinois | — | — |
| Research Site | Boston | Massachusetts | — | — |
| Research Site | St Louis | Missouri | — | — |
| Research Site | Newark | New Jersey | — | — |
| Research Site | Albuquerque | New Mexico | — | — |
| Research Site | Charlotte | North Carolina | — | — |
| Research Site | Winston-Salem | North Carolina | — | — |
| Research Site | Bethlehem | Pennsylvania | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Nashville | Tennessee | — | — |
| Research Site | Houston | Texas | — | — |
| Research Site | Round Rock | Texas | — | — |
| Research Site | Burlington | Vermont | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00436826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 11, 2020 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00436826 live on ClinicalTrials.gov.